Welcome to our dedicated page for Windtree Therapeutics news (Ticker: WINT), a resource for investors and traders seeking the latest updates and insights on Windtree Therapeutics stock.
Windtree Therapeutics, Inc. (WINT) generates news across biotechnology, licensing, financing and corporate diversification activities. Company press releases highlight its evolution from a biotechnology focus into a diversified business with several divisions and an emphasis on becoming a revenue generating company. For followers of WINT news, this means updates can span drug development milestones, asset sales, licensing income opportunities, environmental services initiatives, fintech transactions and capital markets activity.
In the biotech arena, Windtree’s news flow has included interim data and scientific presentations for its cardiovascular drug candidate istaroxime and related SERCA2a activators, as well as decisions to adjust or terminate specific clinical studies based on resources and strategic priorities. The company has also reported on strengthening its patent estate for these cardiovascular assets and later announced an agreement to sell its cardiovascular drug candidates to Seismic Pharmaceutical Holdings, LLC while retaining rights to a share of future proceeds and transferring certain development payables.
Windtree’s communications also cover its acute pulmonary franchise, where a global license agreement for RDS treatments such as SURFAXIN, lyophilized lucinactant and AEROSURF may generate milestone and royalty payments if development and commercialization progress under the licensee. Additional news items describe corporate strategy decisions, including a focus on environmental services and other revenue generating businesses, a letter of intent to acquire CommLoan, Inc. in the fintech and commercial real estate lending technology space, and the outcome of stockholder votes supporting financing flexibility.
Investors tracking WINT-related headlines will also see coverage of financing arrangements, preferred stock conversions, equity line of credit structures, and the company’s exploration of a BNB cryptocurrency treasury strategy, as well as its transition from the Nasdaq Capital Market to over-the-counter trading. Bookmarking this news feed can help readers monitor how Windtree’s mix of biotech assets, licensing agreements and diversified business initiatives evolves over time.
Windtree Therapeutics, Inc. (NasdaqCM: WINT) reported its Q3 2021 financial results, highlighting ongoing clinical advancements for istaroxime as a treatment for early cardiogenic shock. The company posted an operating loss of $8.1 million, a slight improvement from $8.7 million in Q3 2020. R&D expenses increased to $4.7 million, reflecting the development of istaroxime. Windtree raised $3.2 million in October 2021, bringing cash reserves to $24.5 million, expected to sustain operations for the next year. Topline data for istaroxime is anticipated in Q1 2022.
Windtree Therapeutics (NasdaqCM: WINT) announced a Notice of Allowance for a new patent by the USPTO, which will protect the istaroxime formulation until late 2039. This patent covers longer infusion durations aimed at improving treatment outcomes for acute heart failure. Following successful Phase 2 studies showing enhanced cardiac function, Windtree plans to initiate a new study in mid-2022 targeting patients with normal to low blood pressure. The ongoing development of istaroxime continues to position Windtree for future clinical advancement.
Windtree Therapeutics (NasdaqCM: WINT) will host a Key Opinion Leader (KOL) webinar on istaroxime, targeting acute heart failure, on October 19, 2021, at 8:00 am ET. Dr. John Teerlink from UCSF will present insights on current treatments and the unmet needs in acute heart failure. The event will include discussions on istaroxime's clinical development, which includes two Phase 2 trials and a Phase 2 study in early cardiogenic shock. A live Q&A will follow. Registration for the webinar is available here.
Summary not available.
Windtree Therapeutics (NasdaqCM: WINT) announced that Craig Fraser, CEO, will present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on September 22, 2021, at 9:55 am ET. The live webcast will be accessible via the company's Investor Events page. Windtree focuses on late-stage interventions for acute cardiovascular and pulmonary disorders, with its lead candidate, istaroxime, aimed at treating acute heart failure. They also develop AEROSURF® for respiratory distress in infants and are exploring treatments for COVID-19-related respiratory issues.
Windtree Therapeutics (WINT) reported second-quarter results for 2021, highlighting ongoing clinical trials for istaroxime and lucinactant, targeting cardiogenic shock and COVID-19 lung injury respectively. The operating loss reached $45.4 million, largely due to a $37.8 million impairment on rostafuroxin assets. R&D expenses decreased to $4.2 million, and general administrative costs were stable at $3.4 million. A net loss of $37.4 million ($1.42 per share) was recorded. The company maintains a cash position of $30 million, expected to support operations for at least the next year.
Windtree Therapeutics (NasdaqCM: WINT) has appointed Randall White, Ph.D., as Vice President of Clinical Program Management. Dr. White brings over 20 years of pharmaceutical research experience, previously serving at Daiichi Sankyo and Bristol-Myers Squibb. His expertise will support Windtree's clinical development projects. To incentivize his employment, the company granted Dr. White a stock option for 100,000 shares at the closing price on the grant date. Windtree focuses on interventions for acute cardiovascular and pulmonary disorders, with key products including istaroxime and AEROSURF®.
Windtree Therapeutics, focused on acute cardiovascular and pulmonary therapies, announced CEO Craig Fraser's upcoming presentation at the Access to Giving Virtual Investor conference from July 13-15, 2021. Windtree is scheduled to present on July 15, 2021, at 10:00 AM ET. The conference will feature over 50 companies and aims to promote investor education and advocacy, with funds raised directed to financial literacy initiatives. The presentation will be available for replay on the company’s website, and one-on-one meetings can be arranged with management.
Windtree Therapeutics (NasdaqCM: WINT) announced that CEO Craig Fraser will present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on July 13, 2021, at 11:00 am ET. The presentation will cover the company's innovative therapies for acute cardiovascular and pulmonary disorders. Windtree is developing istaroxime for acute heart failure and AEROSURF® for respiratory distress in premature infants. A replay will be available on their investor page.
Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced the appointment of Diane Carman as Senior Vice President and General Counsel, effective July 1, 2021. Ms. Carman, with over 20 years of experience in the biotech sector, has a proven track record in legal compliance, corporate governance, and M&A. She previously served as General Counsel for various companies, including Vitara Biomedical. Her appointment is expected to bolster Windtree's legal framework as it advances late-stage interventions for acute cardiovascular and pulmonary disorders. Ms. Carman received stock options to purchase 150,000 shares as part of her inducement to join the company.
FAQ
What is the current stock price of Windtree Therapeutics (WINT)?
What is the market cap of Windtree Therapeutics (WINT)?
